NYSE:ALife Sciences
Agilent (A) Stock May Be 23% Below Fair Value Despite Digital Pathology Launch
Agilent Technologies is coming off a 3 year gain of about 29.7%, yet its current valuation checks send mixed signals, with the Discounted Cash Flow (DCF) estimate pointing to undervaluation while market multiples lean the other way. The share price around US$146.93 also sits against a mid range value score, which keeps the debate open rather than resolved.
A roughly 29.7% rise over 3 years suggests Agilent Technologies has rewarded patient holders, without being an extreme momentum...